Stericycle, Inc.
Thesis
Stericycle is overvalued due to declining EBITDA, margin erosion from shrinking end markets, and value-destructive acquisitions that have strained its balance sheet. The company faces significant risks including potential asset impairments and ongoing scrutiny from the SEC regarding its accounting practices. With a target price of $38, there is an expected downside of approximately 40% over the next 18 months.
Did it work?
The stock price has increased by 53.3% since the pitch, which contradicts the short thesis that anticipated a significant decline. The thesis highlighted declining EBITDA and margin erosion, but these factors did not materialize in a way that negatively impacted the stock price as expected. Given the substantial time elapsed and the positive price movement, the thesis has failed.
Raw excerpt
No raw excerpt stored.